CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

CRISPR Therapeutics (CRSP) shares have increased 14% in the past month, spurred by positive early-stage trial data for its in vivo gene therapy candidate CTX310, which demonstrated significant reductions in LDL and triglyceride levels. Casgevy, the company's approved ex vivo gene therapy, reported Q1 sales of $14.2 million with 65 treatment centers activated, and CRSP anticipates multiple pipeline updates in 2025, including data for CTX320 and new in vivo programs. Despite facing competition and early-stage pipeline risks, CRISPR's strong cash balance and positive price momentum suggest continued growth potential.

Analysis

CRISPR Therapeutics (CRSP) has demonstrated notable positive momentum, evidenced by a 14% increase in its stock price over the past month, largely attributed to encouraging preliminary results from its in vivo gene therapy candidate, CTX310. This early-stage trial targeting ANGPTL3 for atherosclerotic heart disease indicated dose-dependent reductions in LDL and triglyceride levels of up to 81% and 82%, respectively, a significant milestone given the absence of approved in vivo CRISPR-based therapies. Simultaneously, Casgevy, its approved ex vivo gene therapy developed with Vertex Pharmaceuticals, achieved Q1 sales of $14.2 million, up from $8 million in the preceding quarter, supported by the activation of over 65 treatment centers and nearly 90 patient cell collections. The company anticipates several pipeline updates in 2025, including initial data for CTX320, another in vivo candidate for heart disease, expected by month-end, alongside progress in its CAR-T programs. Despite these advancements and a robust cash reserve of approximately $1.9 billion as of March 2025, CRISPR Therapeutics contends with substantial challenges: the majority of its pipeline is in early clinical development, loss per share estimates for 2025 and 2026 have widened to $5.54 and $4.30 respectively, and the competitive landscape is intense, featuring rivals like Intellia Therapeutics with late-stage in vivo candidates and existing treatments for Casgevy's indications. From a valuation perspective, CRSP trades at a price-to-book ratio of 2.03, below the industry's 3.14 and its own five-year average of 2.41, suggesting a relative discount that must be contextualized by its developmental risks and financial outlook.

Key Decisions for Investors

• Investors should closely monitor upcoming clinical trial readouts, particularly the initial data for CTX320 expected by month-end, as positive results could serve as a significant near-term catalyst.
• Carefully track the commercial ramp-up of Casgevy, including patient uptake and revenue growth, as this is crucial for validating the company's transition to a commercial-stage entity and establishing a stable revenue stream.
• Evaluate the company's progress against the backdrop of its early-stage pipeline, widening loss per share estimates, and the highly competitive gene-editing landscape, balancing the transformative potential of its technology with the inherent risks.
• Consider the stock's current valuation discount relative to the industry, but weigh this against the long development timelines and financial burn rate associated with its extensive research and development programs.